Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Cannabis-based medicines are approved for multiple sclerosis (MS) symptom management.
• Growing evidence supports cannabinoids' therapeutic potential in MS.
• Endocannabinoid systems are present in immune and nervous cells.

Purpose of the Study:

• To review the peripheral and central effects of cannabinoids in MS-related neuroinflammation.
• To examine cannabinoid impacts on remyelination and axon preservation.
• To identify key questions and future research directions.

Main Methods:

• Review of existing literature on cannabis-based treatments in MS models.
• Analysis of cannabinoid mechanisms in demyelination models (EAE, TMEV-IDD).
• Exploration of effects on immune cells, blood-brain barrier, microglia, astrocytes, oligodendrocytes, and neurons.

Main Results:

• Cannabinoids influence immune and nervous system cells via CB1 and CB2 receptors.
• Potential therapeutic actions target neuroinflammation, demyelination, and neuroprotection.
• Evidence from animal models suggests benefits for CNS repair and inflammation resolution.

Conclusions:

• Cannabinoids offer a promising therapeutic avenue for managing MS.
• Further research is needed to fully elucidate their role in remyelination and axon preservation.
• Understanding cannabinoid mechanisms can guide future MS treatment strategies.